Regarding risk differences by sex, Gemmati et al. reported that an unbalance of ACE/ACE2 might show marked differences in the outcomes of COVID-19 in both sexes, given that this unbalance could induce a higher inflammatory mediators/receptors expression; hence, men might show a worse clinical scenario than women, as women could activate a mosaic advantage due to their X-heterozygosity (27). The gene discussed is ACE2; the disease is COVID-19.